Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Sales: 2020-2025

Historic Return on Sales for Apellis Pharmaceuticals (APLS) over the last 5 years, with Sep 2025 value amounting to 0.04%.

  • Apellis Pharmaceuticals' Return on Sales rose 39.00% to 0.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.04%, marking a year-over-year increase of 39.00%. This contributed to the annual value of -0.25% for FY2024, which is 108.00% up from last year.
  • Apellis Pharmaceuticals' Return on Sales amounted to 0.04% in Q3 2025, which was up 114.63% from -0.30% recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Return on Sales high stood at 0.04% for Q3 2025, and its period low was -11.96% during Q4 2021.
  • Moreover, its 3-year median value for Return on Sales was -0.53% (2024), whereas its average is -1.47%.
  • In the last 5 years, Apellis Pharmaceuticals' Return on Sales crashed by 1,096bps in 2021 and then soared by 731bps in 2023.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Return on Sales stood at -11.96% in 2021, then soared by 332bps to -8.65% in 2022, then soared by 731bps to -1.33% in 2023, then skyrocketed by 108bps to -0.25% in 2024, then skyrocketed by 39bps to 0.04% in 2025.
  • Its Return on Sales was 0.04% in Q3 2025, compared to -0.30% in Q2 2025 and -0.29% in Q1 2025.